查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1729537

日本口服抗糖尿病藥物市場報告（依藥物類型（雙胍類、α-葡萄糖苷酶抑制劑、多巴胺D2受體激動劑、SGLT-2抑制劑、DPP-4抑制劑、磺醯脲類、格列奈類））及地區 2025-2033

Japan Oral Anti-Diabetic Drug Market Report by Drug (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, Meglitinides), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 121 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2024年，日本口服抗糖尿病藥物市場規模達24億美元。展望未來， IMARC Group預計到2033年市場規模將達到37億美元，2025-2033年期間的成長率（CAGR）為4.42%。由於生活方式的改變和肥胖率的上升等因素，糖尿病盛行率的上升是推動市場成長的主要因素。

口服抗糖尿病藥物是第 2 型糖尿病治療的關鍵，是一種用於調節身體抵抗胰島素作用或無法產生足夠胰島素的個體的血糖水平的藥物。雖然注射胰島素仍然是糖尿病的主要治療方法，但口服抗糖尿病藥物提供了一種非侵入性的替代方法，並且通常作為阻止疾病進展的第一道防線。這些藥物透過各種機制發揮作用，例如刺激胰臟產生更多的胰島素，減少肝臟的葡萄糖產生，或改善身體組織的胰島素敏感性。

日本口服抗糖尿病藥物市場趨勢：

日本口服抗糖尿病藥物市場是其醫療保健產業的重要部分，反映了該國先進的醫學研究能力和人口挑戰。隨著人口老化和都市化進程加快，包括第 2 型糖尿病在內的生活方式疾病明顯增加。區域市場的一個獨特驅動力是對研發活動的高度重視。 DPP-4 抑制劑和 SGLT2 抑制劑等創新藥物的批准不僅擴大了治療選擇，而且還改善了血糖控制並減少了副作用。影響市場的另一個趨勢是人們對個人化醫療的傾向日益增強。人們意識到糖尿病在個體上的表現不同，開始推動根據遺傳、環境和生活方式因素制定個人化治療方案。因此，使用兩種或兩種以上抗糖尿病藥物的聯合療法越來越受到人們的關注，以實現更好的血糖控制。此外，日本政府在醫療保健方面採取積極態度，推行定期健康檢查和早期發現的政策，間接促進了口服抗糖尿病藥物市場的發展。透過強調預防措施和及時干預，該國不僅解決了眼前的健康需求，而且還減輕了與糖尿病併發症相關的長期醫療成本。除此之外，預計治療方式的引入將在預測期內推動市場成長。

日本口服抗糖尿病藥物市場細分：

藥物洞察：

  • 雙胍類
    • 二甲雙胍
  • α-葡萄糖苷酶抑制劑
  • 多巴胺D2受體激動劑
    • 溴隱亭
  • SGLT-2抑制劑
    • Invokana（卡格列淨）
    • Jardiance（恩格列淨）
    • Farxiga/Forxiga（達格列淨）
    • 舒格列淨（伊普拉格列淨）
  • DPP-4抑制劑
    • 沙格列汀（Onglyza）
    • Tradjenta（利格列汀）
    • Vipidia/Nesina（阿格列汀）
    • Galvus（維格列汀）
  • 磺醯脲類藥物
  • 格列奈類

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外，也提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

  • 日本口服抗糖尿病藥物市場目前表現如何？未來幾年將如何表現？
  • COVID-19 對日本口服抗糖尿病藥物市場有何影響？
  • 日本口服抗糖尿病藥物市場按藥物類型分類是怎樣的？
  • 日本口服抗糖尿病藥物市場的價值鏈分為哪些階段？
  • 日本口服抗糖尿病藥物的關鍵促進因素和挑戰是什麼？
  • 日本口服抗糖尿病藥物市場的結構是怎麼樣的？主要參與者是誰？
  • 日本口服抗糖尿病藥物市場的競爭程度如何？

本報告回答的關鍵問題：

  • 日本口服抗糖尿病藥物市場目前表現如何？未來幾年將如何表現？
  • COVID-19 對日本口服抗糖尿病藥物市場有何影響？
  • 日本口服抗糖尿病藥物市場按藥物類型分類是怎樣的？
  • 日本口服抗糖尿病藥物市場的價值鏈分為哪些階段？
  • 日本口服抗糖尿病藥物的關鍵促進因素和挑戰是什麼？
  • 日本口服抗糖尿病藥物市場的結構是怎麼樣的？主要參與者是誰？
  • 日本口服抗糖尿病藥物市場的競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：日本口服抗糖尿病藥物市場－簡介

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭情報

第5章：日本口服抗糖尿病藥物市場格局

  • 歷史與當前市場趨勢（2019-2024）
  • 市場預測（2025-2033）

第6章：日本口服抗糖尿病藥物市場-細分：依藥物

  • 雙胍類
    • 概述
    • 市場區隔
      • 二甲雙胍
  • α-葡萄糖苷酶抑制劑
    • 概述
  • 多巴胺D2受體激動劑
    • 概述
    • 市場區隔
      • 溴隱亭
  • SGLT-2抑制劑
    • 概述
    • 市場區隔
      • Invokana（卡格列淨）
      • Jardiance（恩格列淨）
      • Farxiga/Forxiga（達格列淨）
      • 舒格列淨（伊普拉格列淨）
  • DPP-4抑制劑
    • 概述
    • 市場區隔
      • 沙格列汀（Onglyza）
      • Tradjenta（利格列汀）
      • Vipidia/Nesina（阿格列汀）
      • Galvus（維格列汀）
  • 磺醯脲類藥物
    • 概述
  • 格列奈類
    • 概述

第7章：日本口服抗糖尿病藥物市場－競爭格局

  • 概述
  • 市場結構
  • 市場參與者定位
  • 最佳獲勝策略
  • 競爭儀錶板
  • 公司評估象限

第8章：關鍵參與者簡介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第9章：日本口服抗糖尿病藥物市場-產業分析

  • 促進因素、限制因素和機遇
    • 概述
    • 驅動程式
    • 限制
    • 機會
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價值鏈分析

第 10 章：附錄

簡介目錄
Product Code: SR112025A15652

Japan oral anti-diabetic drug market size reached USD 2.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.42% during 2025-2033. The rising prevalence of diabetes, due to factors like changing lifestyles and the increasing obesity rates, is primarily driving the market growth.

Oral anti-diabetic drugs, pivotal in the management of type 2 diabetes, are pharmacological agents designed to regulate blood glucose levels in individuals whose bodies either resist the effects of insulin or don't produce enough. While insulin injections remain a primary treatment for diabetes, oral antidiabetic medications offer a non-invasive alternative and often serve as the first line of defense against the progression of the disease. These medications operate through various mechanisms, such as stimulating the pancreas to produce more insulin, reducing the liver's glucose production, or improving insulin sensitivity in body tissues.

Japan Oral Anti-Diabetic Drug Market Trends:

Japan's oral antidiabetic drug market is a critical segment of its healthcare industry, reflecting both the nation's advanced medical research capabilities and its demographic challenges. With an aging population and increasing urbanization, there's been a notable rise in lifestyle diseases, including type 2 diabetes. A distinctive driver in the regional market is the strong emphasis on research and development activities. The approval of innovative drug classes, such as DPP-4 inhibitors and SGLT2 inhibitors, has not only expanded treatment options but also offered improved glycemic control with reduced side effects. Another trend shaping the market is the growing inclination towards personalized medicine. Recognizing that diabetes manifests differently in individuals, there's a push towards tailoring treatments based on genetic, environmental, and lifestyle factors. Consequently, combination therapies, which use two or more antidiabetic drugs, are gaining traction to achieve better blood sugar control. Furthermore, the Japanese government's proactive stance on healthcare, with policies promoting regular health check-ups and early detection, indirectly boosts the oral antidiabetic drug market. By emphasizing preventive measures and timely intervention, the country not only addresses the immediate health needs but also mitigates long-term healthcare costs associated with diabetes-related complications. Apart from this, the introduction of treatment modalities is anticipated to propel the market growth over the forecasted period.

Japan Oral Anti-Diabetic Drug Market Segmentation:

Drugs Insights:

  • Biguanides
    • Metformin
  • Alpha-Glucosidase Inhibitors
  • Dopamine D2 Receptor Agonist
    • Bromocriptin
  • SGLT-2 inhibitors
    • Invokana (Canagliflozin)
    • Jardiance (Empagliflozin)
    • Farxiga/Forxiga (Dapagliflozin)
    • Suglat (Ipragliflozin)
  • DPP-4 inhibitors
    • Onglyza (Saxagliptin)
    • Tradjenta (Linagliptin)
    • Vipidia/Nesina (Alogliptin)
    • Galvus (Vildagliptin)
  • Sulfonylureas
  • Meglitinides

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan oral anti-diabetic drug market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan oral anti-diabetic drug market?
  • What is the breakup of the Japan oral anti-diabetic drug market on the basis of drugs?
  • What are the various stages in the value chain of the Japan oral anti-diabetic drug market?
  • What are the key driving factors and challenges in the Japan oral anti-diabetic drug?
  • What is the structure of the Japan oral anti-diabetic drug market and who are the key players?
  • What is the degree of competition in the Japan oral anti-diabetic drug market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Oral Anti-Diabetic Drug Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Oral Anti-Diabetic Drug Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Oral Anti-Diabetic Drug Market - Breakup by Drugs

  • 6.1 Biguanides
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Metformin
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Alpha-Glucosidase Inhibitors
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Dopamine D2 Receptor Agonist
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Segmentation
      • 6.3.3.1 Bromocriptin
    • 6.3.4 Market Forecast (2025-2033)
  • 6.4 SGLT-2 inhibitors
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2019-2024)
    • 6.4.3 Market Segmentation
      • 6.4.3.1 Invokana (Canagliflozin)
      • 6.4.3.2 Jardiance (Empagliflozin)
      • 6.4.3.3 Farxiga/Forxiga (Dapagliflozin)
      • 6.4.3.4 Suglat (Ipragliflozin)
    • 6.4.4 Market Forecast (2025-2033)
  • 6.5 DPP-4 inhibitors
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2019-2024)
    • 6.5.3 Market Segmentation
      • 6.5.3.1 Onglyza (Saxagliptin)
      • 6.5.3.2 Tradjenta (Linagliptin)
      • 6.5.3.3 Vipidia/Nesina(Alogliptin)
      • 6.5.3.4 Galvus (Vildagliptin)
    • 6.5.4 Market Forecast (2025-2033)
  • 6.6 Sulfonylureas
    • 6.6.1 Overview
    • 6.6.2 Historical and Current Market Trends (2019-2024)
    • 6.6.3 Market Forecast (2025-2033)
  • 6.7 Meglitinides
    • 6.7.1 Overview
    • 6.7.2 Historical and Current Market Trends (2019-2024)
    • 6.7.3 Market Forecast (2025-2033)

7 Japan Oral Anti-Diabetic Drug Market - Competitive Landscape

  • 7.1 Overview
  • 7.2 Market Structure
  • 7.3 Market Player Positioning
  • 7.4 Top Winning Strategies
  • 7.5 Competitive Dashboard
  • 7.6 Company Evaluation Quadrant

8 Profiles of Key Players

  • 8.1 Company A
    • 8.1.1 Business Overview
    • 8.1.2 Product Portfolio
    • 8.1.3 Business Strategies
    • 8.1.4 SWOT Analysis
    • 8.1.5 Major News and Events
  • 8.2 Company B
    • 8.2.1 Business Overview
    • 8.2.2 Product Portfolio
    • 8.2.3 Business Strategies
    • 8.2.4 SWOT Analysis
    • 8.2.5 Major News and Events
  • 8.3 Company C
    • 8.3.1 Business Overview
    • 8.3.2 Product Portfolio
    • 8.3.3 Business Strategies
    • 8.3.4 SWOT Analysis
    • 8.3.5 Major News and Events
  • 8.4 Company D
    • 8.4.1 Business Overview
    • 8.4.2 Product Portfolio
    • 8.4.3 Business Strategies
    • 8.4.4 SWOT Analysis
    • 8.4.5 Major News and Events
  • 8.5 Company E
    • 8.5.1 Business Overview
    • 8.5.2 Product Portfolio
    • 8.5.3 Business Strategies
    • 8.5.4 SWOT Analysis
    • 8.5.5 Major News and Events

9 Japan Oral Anti-Diabetic Drug Market - Industry Analysis

  • 9.1 Drivers, Restraints and Opportunities
    • 9.1.1 Overview
    • 9.1.2 Drivers
    • 9.1.3 Restraints
    • 9.1.4 Opportunities
  • 9.2 Porters Five Forces Analysis
    • 9.2.1 Overview
    • 9.2.2 Bargaining Power of Buyers
    • 9.2.3 Bargaining Power of Suppliers
    • 9.2.4 Degree of Competition
    • 9.2.5 Threat of New Entrants
    • 9.2.6 Threat of Substitutes
  • 9.3 Value Chain Analysis

10 Appendix